New Compound MCH11 Reduces Alcohol Intake in Mice, Shows Promise

Research conducted at the Miguel Hernández University of Elche (UMH) in Spain has identified a new compound, MCH11, that significantly reduces alcohol consumption and the motivation to drink in mice. The study, which highlights notable differences in efficacy between male and female subjects, opens the door to potential personalized treatments for alcohol use disorder (AUD).

The findings, published in the journal Biomedicine & Pharmacotherapy, stem from four years of collaborative research by experts from UMH’s Institute of Neurosciences, the Institute for Health and Biomedical Research of Alicante (ISABIAL), and the Primary Care Addiction Research Network (RIAPAD). Alcohol use disorder affects millions globally, leading to approximately 2.6 million deaths each year. Current therapies have significant limitations, as noted by Abraham Torregrosa, the first author of the study, who points out that up to 70% of patients relapse within the first year of treatment.

The research team focused on the endocannabinoid system, which plays a crucial role in regulating pleasure, motivation, and stress—all key factors in alcohol addiction. In individuals with AUD, this system is often imbalanced, resulting in decreased levels of 2-arachidonoylglycerol (2-AG), a molecule associated with well-being and impulse control. MCH11 works by inhibiting monoacylglycerol lipase, an enzyme responsible for degrading 2-AG. By blocking this enzyme, MCH11 increases the availability of 2-AG in the brain, which helps to reduce both the impulse to drink and withdrawal symptoms.

Jorge Manzanares, the study leader, explains that the results indicate MCH11 engages with mechanisms in the nervous system that help control drinking impulses, while avoiding undesirable side effects observed in other treatments. The compound has shown effectiveness in mice without impairing motor or cognitive functions.

The sex-dependent differences in response to treatment were striking. The research indicated that male mice responded effectively to low and medium doses of MCH11, while female mice required higher doses for comparable effects. “This highlights the importance of considering sex differences in the development of treatment protocols,” Manzanares adds.

Beyond behavioral improvements, genetic analysis conducted via PCR revealed that MCH11 corrected certain genetic alterations associated with AUD in both male and female mice, although females needed higher doses for similar effects. This discovery raises the potential for MCH11 to be part of a tailored treatment plan based on sex.

The research team also explored the effects of combining MCH11 with topiramate, a medication already in use for AUD. They found that this combination enhanced treatment efficacy, suggesting a pathway for developing more effective, personalized therapies for alcohol-related disorders.

While the results are promising, Manzanares cautions that they are still preliminary. “There is a long road from demonstrating drug efficacy in animal models to applying it in patients,” he states. The research team, which includes Torregrosa, María García Gutiérrez, Daniela Navarro, and Francisco Navarrete, continues to work towards translating these findings into clinical applications.

The implications of this research could significantly impact how alcohol use disorder is treated in the future, paving the way for more effective, personalized approaches to combatting this widespread addiction. Further studies will be essential to explore the full potential of MCH11 and its implications for human health.